SCHEMBL20164475

SCHEMBL20164475

CCCNc1nc(NC)nc2c(NCC(C)(C)O)nc(NC)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.44
TLR7 Q9NYK1 3/20 0.34
KMT2A Q03164 1/20 0.33
LRRK2 Q5S007 1/20 0.32
TLR8 Q9NR97 2/20 0.32
IDH2 P48735 1/20 0.32
APP P05067 2/20 0.31
BCHE P06276 2/20 0.31
ACHE P22303 2/20 0.31
CCNE1 P24864 2/20 0.31
CDK2 P24941 2/20 0.31
CDK5 Q00535 2/20 0.31
CCNT1 O60563 1/20 0.31
CDK7 P50613 1/20 0.31
CDK9 P50750 1/20 0.31
CCNH P51946 1/20 0.31
CDK5R1 Q15078 1/20 0.31
PDE4A P27815 1/20 0.30
PDE10A Q9Y233 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL20164584 0.98 SLC29A1 (0.43) SLC29A1TLR7KMT2ALRRK2TLR8
SCHEMBL20164502 0.88 SLC29A1 (0.48) SLC29A1TLR7KMT2ATLR8APP
SCHEMBL20164707 0.87 LRRK2 (0.36) SLC29A1LRRK2IDH2CCNE1CDK2
SCHEMBL20164494 0.87 SLC29A1 (0.44) SLC29A1TLR7KMT2ALRRK2TLR8
Hydrochloric Acid SCHEMBL20164610 0.87 SLC29A1 (0.47) SLC29A1TLR7KMT2ATLR8APP
SCHEMBL20179413 0.87 SLC29A1 (0.43) SLC29A1TLR7APPBCHEACHE
Hydrochloric Acid SCHEMBL20164775 0.86 SLC29A1 (0.43) SLC29A1TLR7KMT2ALRRK2TLR8
Hydrochloric Acid SCHEMBL20164642 0.86 LRRK2 (0.36) SLC29A1LRRK2IDH2CCNE1CDK2
Hydrochloric Acid SCHEMBL20164712 0.85 SLC29A1 (0.42) SLC29A1TLR7APPBCHEACHE
SCHEMBL20164518 0.85 SLC29A1 (0.38) SLC29A1TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US claimed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP claimed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US claimed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US claimed
CN-121729233-A GAL475 compositions and methods of use thereof 纽瑞姆制药(1991)有限公司 2026-03-24 CN disclosed
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 US disclosed
WO-2025037248-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF NEURIM PHARMACEUTICALS (1991) LTD. (IL) 2025-02-20 WO disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
EP-3316890-B1 NOVEL BREATHING CONTROL MODULATING COMPOUNDS, AND METHODS OF MAKING AND USING SAME NEURAD LTD (IL) 2023-09-06 EP disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same NEURAD LTD. (IL) 2019-05-21 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same NEURAD LTD. (IL) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141953-A1 Novel Breathing Control Modulating Compounds, and Methods of Making and Using Same MTNR1B, CHRM3, PER2 SLC29A1 4472/4885TLR7 4569/4885KMT2A 2456/4885
US-20250057848-A1 GAL475 COMPOSITIONS AND METHODS OF USE THEREOF GPR119, GPR35, GPR55 SLC29A1 2077/4885TLR7 2851/4885KMT2A 1865/4885
US-10294228-B2 Breathing control modulating compounds, and methods of making and using same MTNR1B, PDE3A, CHRM3 SLC29A1 4518/4885TLR7 4584/4885KMT2A 2528/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.